Financial Highlights

In the fiscal year ended March 2026, performance remained solid in the Americas, EMEA, and AP regions, while the impact of healthcare cost containment policies in China continued. In addition, the recognition of goodwill impairment losses related to a consolidated subsidiary resulted in a year-on-year decline in both revenue and profit.
Sales came in at 98.3% of the prior year (105.1% excluding China), while operating income was 59.2% and quarterly profit was 66.1% of the prior year level. By region, sales declined in China and Japan, while performance in the Americas, EMEA, and AP remained strong, driven by the hematology and urinalysis segments. In particular, EMEA continued to secure large-scale contracts in the hemostasis segment, while AP achieved double-digit growth in Q4. Although the market environment in China remained challenging, the Company steadily advanced initiatives that will contribute to future growth, including the launch of new products in Japan and the Americas, the full-scale expansion of the hemostasis business in Europe and the United States, and business expansion in emerging markets.
In the fiscal year ending March 2027, the impact of healthcare cost containment policies and intensifying competition in China is expected to continue. Under these conditions, the Company will continue to focus on its Diagnostics business and drive new product launches to meet customer expectations. In addition, it will expand its business in emerging markets and accelerate the development of the hemostasis business, while advancing a review of its business portfolio to improve both growth and profitability.